Capital International Inc. CA Sells 19,686 Shares of Zoetis Inc. $ZTS

Capital International Inc. CA lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 66.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,060 shares of the company’s stock after selling 19,686 shares during the period. Capital International Inc. CA’s holdings in Zoetis were worth $1,472,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC raised its stake in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Financial Consulate Inc. purchased a new position in Zoetis in the 3rd quarter worth approximately $39,000. SJS Investment Consulting Inc. increased its holdings in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the last quarter. TruNorth Capital Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at $42,000. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Zoetis during the 2nd quarter valued at $47,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.6%

ZTS opened at $119.82 on Thursday. The business has a 50 day simple moving average of $125.75 and a two-hundred day simple moving average of $132.31. The firm has a market capitalization of $50.58 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 1.84 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a one year low of $115.25 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company earned $1.40 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZTS. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. KeyCorp assumed coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.